Analyzing Oruka Therapeutics (ORKA) and Its Rivals

Oruka Therapeutics (NASDAQ:ORKA) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it weigh in compared to its rivals? We will compare Oruka Therapeutics to similar businesses based on the strength of its risk, earnings, dividends, profitability, analyst recommendations, valuation and institutional ownership.

Valuation and Earnings

This table compares Oruka Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oruka Therapeutics	N/A	-$5.34 million	-4.62
Oruka Therapeutics Competitors	$556.25 million	$6.13 million	-36.33

Oruka Therapeutics’ rivals have higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Oruka Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-20.18%	-19.51%
Oruka Therapeutics Competitors	-1,887.40%	-40.50%	-25.93%

Insider and Institutional Ownership

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of shares of all “Diagnostic substances” companies are owned by institutional investors. 30.9% of Oruka Therapeutics shares are owned by insiders. Comparatively, 13.1% of shares of all “Diagnostic substances” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Oruka Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Oruka Therapeutics’ rivals have a beta of 1.31, meaning that their average share price is 31% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Oruka Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	0	0	6	2	3.25
Oruka Therapeutics Competitors	848	799	1347	23	2.18

Oruka Therapeutics currently has a consensus price target of $43.17, indicating a potential upside of 55.61%. As a group, “Diagnostic substances” companies have a potential upside of 31.15%. Given Oruka Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Oruka Therapeutics is more favorable than its rivals.

Summary

Oruka Therapeutics beats its rivals on 10 of the 13 factors compared.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.